

---

Thursday,  
May 5, 2022  
17:30 CET

---

# The NASDAQ IPO Path for Italian Life Science Companies: Genenta Science's Case Study

[Register to the  
webinar](#)



# Speakers:

- **Andrea Messuti (LCA Studio Legale)**
- **Ettore Santucci (Goodwin)**
- **Pierluigi Paracchi (Genenta)**
- **Aparna Beeram (Roth Capital Partners)**
- **Federica Draghi (Genextra)**
- **Leonardo Vingiani (Federchimica Assobiotec)**

17:30	<b>Leonardo Vingiani opens the webinar with welcoming remarks</b>
17:35	<b>Ettore Santucci and Andrea Messuti introduce the panelists and the agenda</b>
17:40	<b>Pierluigi Paracchi describes how Genenta Science prepared for a successful NASDAQ IPO: from early stage backing to advance the science in the lab, to VC rounds to fund R&amp;D, pre-clinical and clinical studies, to the organizational growth and infrastructure build necessary to approach the listed market, culminating with the selection of a lead underwriter.</b>
17:55	<b>Aparna Beeram illustrates key attributes of an early stage life sciences company to be suitable for a NASDAQ IPO and the critical features that public market investors look for in assessing the issuer's potential as a successful listed company.</b>
18:10	<b>Federica Draghi illustrates the Italian ecosystem for hatching and supporting promising life sciences companies in their early stage, the private and public capital sources available for pre-IPO growth, and opportunities/challenges for companies that wish to get ready for the listed market.</b>
18:25	<b>Leonardo Vingiani concludes with an institutional message to its members and opens the Q&amp;A segment</b>
18:30	<b>Q&amp;A</b>
18:45	<b>Meeting ends</b>